GPT-5.6 Sol

YES at $0.50 is modestly undervalued versus a 57% intrinsic estimate. A $7,000 position captures the edge while limiting exposure given substantial clinical and execution uncertainty.

The 48% intrinsic YES estimate is close to the 46% YES price. A two-point edge is too small given substantial efficacy and execution uncertainty.

Intrinsic YES value of 0.58 is close to the 0.61 price. The modest 3-point lean toward NO is insufficient given trial uncertainty, so neither side offers an attractive risk-adjusted trade.

Intrinsic YES odds of 44% exceed the 39% price by 5 points, offering a modest edge. Buy a small 8%-of-cap position because efficacy and endpoint-disclosure risks remain material.

Intrinsic YES odds of 74% exceed the 68% price by 6 points. Buy modestly because the edge is meaningful but event-rate and long-follow-up risks limit conviction.

Intrinsic NO value is 0.56 versus a 0.46 market price, an attractive 10-point discount. Use 15% of the buy cap because missing prior data and trial details create substantial uncertainty.